Preparation method of voriconazole and its intermediates
By recycling mother liquor from voriconazole condensate isomers under acidic conditions, the method addresses the challenges of low selectivity and high costs in voriconazole production, achieving efficient and cost-effective large-scale production.
Patent Information
- Application Number
- CN202080007221.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-02-19
- Filing Date
- 2020-02-18
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-02-18
AI Technical Summary
Existing methods for preparing voriconazole face challenges in achieving high selectivity and yield of the desired enantiomers, leading to high production costs and resource waste, which are unsuitable for large-scale industrial production.
A method involving the recycling of mother liquor from voriconazole condensate isomers under acidic conditions to produce compounds 3 and 4, followed by bromination, condensation, and hydrogenation to obtain voriconazole, utilizing simple reaction conditions and improving raw material utilization.
This method enhances the utilization rate of raw materials, reduces production costs, and minimizes resource waste, making it suitable for large-scale industrial production.
Smart Images

Figure FDA0004879902960000011 
Figure FDA0004879902960000021 
Figure GPA0000306690450000011
Abstract
Description
[0001] This application claims the priority of Chinese patent application filed with the China Patent Office on February 19, 2019, with application number 201910121961.0 and invention name “Method for preparing voriconazole and its intermediates”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The invention relates to a preparation method of voriconazole and an intermediate thereof, and belongs to the technical field of medicines. Background Art
[0003] The chemical name of voriconazole is (2R, 3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidine)-1-(1H-1,2,4-triazol-1-yl)-2-butanol, and its chemical formula is as follows:
[0004]
[0005] Voriconazole is a broad-spectrum triazole antifungal drug with the following indications: invasive aspergillosis; severe invasive infections caused by Candida species (including Candida krusei) that are resistant to fluconazole; and severe infections caused by Actinomyces and Fusarium species.
[0006] The methods for preparing voriconazole reported in the literature can be summarized into two main routes: one route is to first prepare the (2R, 3S / 2S, 3R) racemate and then resolve it to prepare voriconazole; the second route is to use a chiral reagent (catalyst or ligand) for asymmetric condensation to directly prepare voriconazole.
[0007] The above two methods generally involve the following compound 2, i.e., voriconazole condensate, which is hydrogenated to obtain voriconazole or a racemate, which is then resolved to obtain voriconazole.
[0008]
[0009] The higher the ratio of the 2R, 3S / 2S, 3R enantiomer to the 2R, 3R / 2S, 3S enantiomer of compound 2, the more favorable it is for the subsequent resolution of voriconazole. The prior art discloses a variety of methods for increasing the ratio of the 2R, 3S / 2S, 3R enantiomer to the 2R, 3R / 2S, 3S enantiomer of compound 2. CN1026788C discloses a method of directly condensing the intermediate 4-chloro-5-fluoro-6-ethylpyrimidine with 2-(1H-1,2,4-triazole)-2,4-difluoroacetophenone under the action of a strong base, and then separating the two pairs of enantiomers through a chiral column. However, such a method lacks selectivity, and the ratio of the two pairs of enantiomers of the target compound 2 (2R, 3S / 2S, 3R) to (2R, 3R / 2S, 3S) is only 1:1.1, and the yield is low. CN1076019C discloses a method of first brominating the intermediate 4-chloro-5-fluoro-6-ethylpyrimidine, and then performing a Reformatsky reaction with 2-(1H-1,2,4-triazole)-2,4-difluoroacetophenone under the catalytic action of excess zinc, iodine and a small amount of lead to directional generate a large proportion of the desired 2R, 3S / 2S, 3R enantiomers. Since CN1076019C adopts directional synthesis technology, the conversion rate and yield are higher than the chiral column separation method disclosed in CN1026788C. In addition, the operation of directional synthesis technology is also relatively simple. However, the ratio of the (2R, 3S / 2S, 3R) enantiomer to the (2R, 3R / 2S, 3S) enantiomer generated by the directional synthesis technology is only about 9:1, so there is still a large amount of (2R, 3R / 2S, 3S) enantiomer in the mother liquor.
[0010] In addition, prior art such as CN1919846A and CN103788073A discloses a method for asymmetric induction reaction by adding transition metal catalyst and chiral ligand (reagent) in the condensation process. However, such a method also has the following problems at present. One is that expensive and difficult to obtain transition metal catalyst in large quantities are needed in asymmetric synthesis. Therefore, at present, this method is still in the stage of preparing voriconazole samples on a small scale in the laboratory, and the requirements of cost control for industrial production cannot be met. The second is that due to the selectivity problem of asymmetric synthesis, the ratio of (2R, 3S / 2S, 3R) enantiomer to (2R, 3R / 2S, 3S) enantiomer is limited in improvement, and a certain proportion of isomeric impurities are still occupied in the product, so the final subsequent purification still needs to be split.
[0011] In summary, according to the prior art method, voriconazole or its intermediate compound 2 is prepared. Due to the limitations of theory and large-scale production on cost control, although some parameters can be optimized, the utilization rate of raw materials and auxiliary materials cannot be greatly improved in the industrial production process. In order to prepare voriconazole API with higher yield and lower production cost, it is necessary to develop a new technical solution. Such a technical solution can improve the utilization rate of raw materials and auxiliary materials used to prepare voriconazole, thereby reducing resource waste and protecting the environment, and can minimize production costs, which is more conducive to large-scale industrial production. Summary of the invention
[0012] The present invention provides a method for preparing voriconazole and its intermediates by using voriconazole condensate isomers. The method has the advantages of simple reaction conditions and simultaneous recovery of two raw materials, and is therefore very suitable for large-scale industrial cyclic production. The method of the present invention recycles the mother liquor for preparing the voriconazole condensate, thereby improving the utilization rate of the raw materials and auxiliary materials for preparing voriconazole, reducing resource waste and protecting the environment, and can reduce the production cost to the maximum extent.
[0013] The present invention provides a method for preparing a voriconazole intermediate, comprising the following steps: using a voriconazole condensation product isomer, i.e., compound 2 or a salt thereof as a raw material, reacting and post-treating under acidic conditions to obtain compound 3 and compound 4, and the specific reaction formula is as follows:
[0014]
[0015] The compound 2 is a substance having two chiral centers with 2S, 3S or 2R, 3R or 2S, 3R or 2R, 3S configurations, or a mixture of two or more of the above substances; preferably, the compound 2 is mainly a mixture of enantiomers with a 2S, 3S / 2R, 3R configuration, and may also contain a small amount of a mixture of enantiomers with a 2R, 3S / 2S, 3R configuration; more preferably, compound 2 is mainly derived from the mother liquor for preparing voriconazole condensate.
[0016] In one embodiment, the acidic condition refers to an acidic aqueous solution or a mixture of an acidic aqueous solution and an organic solvent.
[0017] In another embodiment, the acid of the acidic aqueous solution is selected from hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, nitric acid and phosphoric acid.
[0018] In another embodiment, the concentration of the acidic aqueous solution is 2 mol / L to 5 mol / L.
[0019] In one embodiment, the molar ratio of the compound 2 or its salt to the acid is 1:2 to 1:20, preferably 1:5 to 1:10.
[0020] In another embodiment, the organic solvent is selected from hydrocarbons, halogenated hydrocarbons, esters, ketones or ethers or combinations thereof; wherein the hydrocarbons or halogenated hydrocarbons are preferably dichloromethane, toluene, cyclohexane; wherein the ethers are preferably isopropyl ether, methyl tert-butyl ether, dioxane, tetrahydrofuran; the ketones are preferably acetone, butanone; and the esters are preferably ethyl acetate, isopropyl acetate, methyl acetate.
[0021] In one embodiment, the molar volume ratio of the compound 2 or its salt to the organic solvent is 5 to 15 mol / ml, preferably 5 to 10 mol / ml.
[0022] In another embodiment, the temperature of the reaction is 40-90°C.
[0023] In one embodiment, the reaction time is 2 to 12 hours, preferably 5 to 10 hours.
[0024] In addition, the present invention also provides a method for preparing voriconazole, comprising the following steps: using the above method to prepare compound 3 and compound 4, using the thus obtained compound 3 and compound 4 as raw materials, first brominating compound 3, and then condensing with compound 4 to prepare compound 2' with a configuration of 2S, 3R / 2R, 3S, and then hydrogenating, splitting, and refining to obtain voriconazole. The specific reaction route is as follows:
[0025]
[0026] The specific method for preparing voriconazole from compound 3 and compound 4 can be found in the examples in this specification or in the prior art, such as CN1076019C.
[0027] Compared with the prior art, the advantages of the method of the present invention are embodied in the following aspects:
[0028] (1) The starting raw material compound 2 used in the method of the present invention is mainly solid waste or impurities generated in the process of preparing compound 2' in the prior art. Therefore, the method of the present invention is a clean production method of "turning waste into treasure". The method of the present invention can greatly improve the utilization rate of raw materials and auxiliary materials used in the preparation of voriconazole in the prior art, save resources and protect the environment, not only reduce costs, but also make the production of voriconazole recyclable.
[0029] (2) The method of the present invention can prepare two substances, Compound 3 and Compound 4, using simple reaction conditions. Compared with the scheme for preparing Compound 3 and Compound 4 in the prior art, the method of the present invention has the advantages of short synthesis steps, high yield, low cost, and easier large-scale industrial production. DETAILED DESCRIPTION
[0030] The following examples are used to further illustrate the present invention. These examples exemplarily illustrate the method for preparing voriconazole and its intermediates according to the present invention, which are only for illustrative purposes and do not limit the scope of the present invention in any aspect.
[0031] Example 1
[0032] Preparation of 4-chloro-6-ethyl-5-fluoropyrimidine and 2',4'-difluoro-2-[1-(1H-1,2,4-triazolyl)]acetophenone
[0033] 38.3 g of 2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1,2,4-triazol-1-yl)butan-2-ol (mainly 2S, 3S / 2R, 3R, with a small amount of 2R, 3S / 2S, 3R) was added to a flask, and the mixture was heated to 60-70° C. in 500 ml of 1 mol / L dilute hydrochloric acid for 6-7 hours. After the reaction, the mixture was cooled to 0° C., the pH value was adjusted to 7-8 with ion membrane liquid alkali, and the mixture was extracted with dichloromethane to obtain a mixed solution of compound 3 and compound 4. The mixture was distilled under reduced pressure, and the remaining solid after distillation was compound 4. A total of 22 g of compound 4 was obtained, with a purity of 92% and a yield of 98.7%. The distilled fraction was first distilled under normal pressure to distill off the solvent dichloromethane, and then distilled under reduced pressure. The distillate was compound 3, and 14.2 g of compound 3 was obtained, with a purity of 99.1% and a yield of 88.4%.
[0034] Example 2
[0035] Preparation of 4-chloro-6-ethyl-5-fluoropyrimidine and 2',4'-difluoro-2-[1-(1H-1,2,4-triazolyl)]acetophenone
[0036] 38.3 g of 2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1,2,4-triazol-1-yl)butan-2-ol (mainly 2S, 3S / 2R, 3R, with a small amount of 2R, 3S / 2S, 3R) was added to a flask, heated to 40-50° C. in 380 ml of 3 mol / L sulfuric acid, reacted for 10 hours, cooled to room temperature after the reaction, adjusted the pH value to 7-8 with ion membrane liquid alkali, extracted with ethyl acetate to obtain a mixed solution of compound 3 and compound 4, and distilled under reduced pressure. The remaining solid after distillation was compound 4, and a total of 21 g of compound 4 was obtained, with a purity of 90% and a yield of 94.2%. The distilled fraction was first distilled under normal pressure to distill off the solvent ethyl acetate, and then distilled under reduced pressure. The distillate was compound 3, and 13.6 g of compound 3 was obtained, with a purity of 99.0% and a yield of 84.6%.
[0037] Example 3
[0038] Preparation of 4-chloro-6-ethyl-5-fluoropyrimidine and 2',4'-difluoro-2-[1-(1H-1,2,4-triazolyl)]acetophenone
[0039] 38.3 g of 2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1,2,4-triazol-1-yl)butan-2-ol (mainly 2S, 3S / 2R, 3R, with a small amount of 2R, 3S / 2S, 3R), 380 ml of dioxane and 11.5 g of trifluoroacetic acid were added to a flask, and the temperature was raised to 70-90° C. for reaction for 3-5 hours. After the reaction, the temperature was lowered to room temperature, the pH value was adjusted to 7-8 with ion membrane alkali, and the mixture was extracted with dichloromethane to obtain a mixed solution of compound 3 and compound 4, which was distilled under reduced pressure. The remaining solid after distillation was compound 4, and a total of 20 g of compound 4 was obtained with a purity of 91% and a yield of 89.6%. The distilled fraction was first subjected to atmospheric distillation to distill off the solvent dichloromethane, and then subjected to reduced pressure distillation to obtain compound 3, 13.7 g of compound 3 was obtained with a purity of 99.3% and a yield of 85.3%.
[0040] Example 4
[0041] Preparation of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol
[0042] 38.3 g of 2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1,2,4-triazol-1-yl)butan-2-ol (mainly 2S, 3S / 2R, 3R, with a small amount of 2R, 3S / 2S, 3R), 190 ml of dioxane, 190 ml of water, and 50 ml of concentrated hydrochloric acid were added to a flask, and the temperature was raised to 50-70° C. for reaction for 5-7 hours. After the reaction, the temperature was lowered to room temperature, and the pH value was adjusted to 7-8 with ion membrane liquid alkali. The mixture was extracted with dichloromethane to obtain a mixed solution of compound 3 and compound 4, and the mixture was distilled under reduced pressure. The remaining solid after distillation was compound 4. The distilled fraction was first distilled under normal pressure to distill off the solvent dichloromethane, and then distilled under reduced pressure to obtain a distillate of compound 3. Compound 3 was brominated and reacted with compound 4 in the presence of zinc powder and zinc chloride to undergo a Reformatsky condensation reaction, followed by hydrogenation and dechlorination under Pd / H2. After chiral resolution and purification, 8.7 g of (2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1,2,4-triazol-1-yl)butan-2-ol) (i.e., voriconazole) was obtained with a purity of 99.5% and a yield of 24%.
Claims
1. A method for preparing a voriconazole intermediate, The following steps are involved: The following compound 2 or its salt is used as a raw material, and under acidic conditions, the reaction and post-treatment are performed to obtain compound 3 and compound 4: The compound 2 is a substance having two chiral centers with 2S, 3S or 2R, 3R or 2S, 3R or 2R, 3S configurations, or a mixture of two or more of the above substances.
2. The method according to claim 1, wherein the compound 2 is mainly a mixture of 2S, 3S / 2R, 3R configuration enantiomers.
3. The method according to claim 1, wherein the compound 2 is mainly derived from the mother liquor for preparing voriconazole condensate.
4. The method according to claim 1, wherein the acidic condition refers to an acidic aqueous solution or a mixture of an acidic aqueous solution and an organic solvent.
5. The method according to claim 4, wherein the acidic aqueous solution is selected from aqueous solutions of hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, nitric acid and phosphoric acid.
6. The method according to any one of claims 1 to 5, wherein the molar ratio of the compound 2 or its salt to the acid producing the acidic condition is 1:2 to 1:
20.
7. The method according to claim 6, wherein the molar ratio of the compound 2 or its salt to the acid producing the acidic condition is 1:5 to 1:
10.
8. The method according to claim 4, wherein the organic solvent is selected from hydrocarbons or halogenated hydrocarbons, esters, ketones, ethers or combinations thereof.
9. The method according to claim 8, wherein the hydrocarbon or halogenated hydrocarbon is dichloromethane, toluene, or cyclohexane; the ether is isopropyl ether, methyl tert-butyl ether, dioxane, or tetrahydrofuran; the ketone is acetone or butanone; and the ester is ethyl acetate, isopropyl acetate, or methyl acetate.
10. The method according to claim 4, wherein the molar volume ratio of the compound 2 or its salt to the organic solvent is 5 to 15 mol / ml.
11. The method according to claim 10, wherein the molar volume ratio of the compound 2 or its salt to the organic solvent is 5 to 10 mol / ml.
12. The method according to claim 1, wherein the reaction temperature is 40-90°C.
13. The method according to claim 1, wherein the reaction time is 2-12 hours.
14. The method according to claim 13, wherein the reaction time is 5-10 hours.
15. A method for preparing voriconazole, The following steps are involved: Compound 3 and Compound 4 are prepared by the method according to any one of claims 1 to 14. Compound 3 and Compound 4 are used as raw materials. Compound 3 is first brominated and then subjected to condensation reaction with Compound 4 to prepare Compound 2' with a configuration of 2S, 3R / 2R, 3S. Voriconazole is then obtained by hydrogenation, splitting and refining. The synthetic route is as follows:
